Inflammation Research

, Volume 45, Issue 10, pp 519–523 | Cite as

Hepatobiliary excretion of cysteinyl leukotrienes in three experimental models of acute hepatic injury

  • H. M. Omar
  • R. A. Sanders
  • J. B. WatkinsIII
Original Research Papers


The acute phase response to chemically-induced organ damage involves inflammation and the production of leukotrienes. The liver ordinarily takes up, metabolizes and excretes into bile cysteinyl leukotrienes, but the effect of hepatic injury on these processes is unknown. The hepatic uptake and biliary excretion of LTC4 was studied in male Sprague-Dawley rats after exposure to either streptozotocin (45 mg/kg iv 30 days before experimentation), estradiol-17 β-valerate (1mg/kg sc once a week for 3 weeks) or lipopolysaccharide/d-galactosamine (33 μg/kg ip; 300 mg/kg ip at 6 h and 3 h, respectively, before experimentation). Acute liver injury is produced by these treatment paradigms. Glucose concentrations and activities of several marker enzymes in plasma were measured to demonstrate hepatic injury. Biliary excretion of3H-LTC4 was similar to normal control rats in the three types of acute liver injury. Bile flow rates after3H-LTC4 injection were reduced in lipopolysaccharide-pretreated rats and increased in estradiol-treated animals. Total biliary excretion of leukotrienes was not altered in any disease group. Thus, these models of acute hepatic injury do not appear to influence the hepatobiliary clearance of leukotrienes.

Key words

Leukotrienes Streptozotocin Estradiol Lipopolysaccharide Galactosamine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Krell H. Eicosanoid and bile secretion. In: Siegers CP, Watkins JB III, editors. Biliary Excretion of Drugs and Other Chemicals vol 8/4. Stuttgart: Fischer, 1991:435–54.Google Scholar
  2. [2]
    Richards CD, Gauldie J. Role of cytokines in acute-phase response. In: Aggarwal BB, Puri RK, editors. Human cytokines: their role in disease and therapy. Boston: Blackwell, 1995:253–96.Google Scholar
  3. [3]
    Andus T, Holstege A. Role of cytokines in hepatic and hepatobiliary disease. In: Aggarwal BB, Puri RK, editors. Human cytokines: their role in disease and therapy. Boston: Blackwell, 1995:623–40.Google Scholar
  4. [4]
    Gallin JI, Goldstein IM, Synderman R. Overview. In: Gallin JI, Goldstein IM, Synderman R, editors. Inflammation: basic principles and clinical correlates. New York: Raven Press, 1988:1–3.Google Scholar
  5. [5]
    Hammarstrom W. Leukotrienes. Ann Rev Biochem 1983;52: 355–77.CrossRefGoogle Scholar
  6. [6]
    Tiegs G, Wendel A. Leukotriene-mediated liver injury. Biochem Pharmacol 1988;37:2569–73.CrossRefGoogle Scholar
  7. [7]
    Hagmann W, Hacker HJ, Buchhalz U, Resident mast cells are the main initiators of anaphylactic leukotriene production in the liver. Hepatology 1992;16:1477–84.CrossRefGoogle Scholar
  8. [8]
    Ishikawa T, Muller M, Klunemann C, Schaub T, Keppler D. ATP-dependent primary active transport of cysteinyl leukotriene across liver canalicular membrane. J Biol Chem 1990;265:19279–86.PubMedGoogle Scholar
  9. [9]
    Hagmann W, Parthe S, Kaiser I. Uptake, production and metabolism of cysteinyl leukotrienes in the isolated perfused rat liver: inhibition of leukotriene uptake by cyclosporine. Biochem J 1989;261:611–6.CrossRefGoogle Scholar
  10. [10]
    Keppler D, Hagmann W, Rapp S, Denzlinger C, Koch HK. The relation of leukotrienes to liver injury. Hepatology 1985;5:883–91.CrossRefGoogle Scholar
  11. [11]
    Decker K. Eicosanoids, signal molecules of liver cells. Semin Liver Dis 1985;5:175–90.CrossRefGoogle Scholar
  12. [12]
    Fallon MB, Anderson JM, Boyer JL. Intrahepatic cholestasis. In: Schiff L, Schiff ER, editors. Diseases of the Liver, vol. 1. Philadephia: Lippincott, 1993:343–61.Google Scholar
  13. [13]
    Chiou GC, Yao QS, Chang MS, Okawara T. Prevention and treatment of ocular inflammation with a new class of non-steroidal anti-inflammatory agents. J Ocul Pharmacol 1994;10:335–47.CrossRefGoogle Scholar
  14. [14]
    Liu P, Fisher MA, Farhood A, Smith CW, Jaeschke H. Beneficial effects of extracellular glutathione against endotoxin-induced liver injury. Circ Shock 1994;43:64–70.PubMedGoogle Scholar
  15. [15]
    Iwai M, Jungermann K. Mechanism of action of cysteinyl leukotrienes on glucose and lactate balance and on flow in perfused rat liver. Eur J Biochem 1989;180:273–81.CrossRefGoogle Scholar
  16. [16]
    Kolb H, Kronck KD. Lessons from the low-dose streptozotocin model in mice. Diabet Rev 1993;1:116–26.Google Scholar
  17. [17]
    Burkart V, Kolb H. Protection of islet cells from inflammatory cell death in vitro. Clin Exper Immunol 1993;33:273–8.Google Scholar
  18. [18]
    Watkins JB III, Sanders RA. Diabetes mellitus-induced alterations of hepatobiliary function. Pharmacol Rev 1995;47:1–23.PubMedGoogle Scholar
  19. [19]
    Shiratori Y, Tanaka M, Umihara J, Kawase T, Shiina S, Sugimoto T. Leukotriene inhibitors modulate hepatic injury induced by lipopolysaccharide-activated macrophages. Hepatology 1990;10:51–61.CrossRefGoogle Scholar
  20. [20]
    Hagmann W, Denzlinger C, Keppler D. Role of peptide leukotrienes and their hepatobiliary elimination in endotoxin action. Circ Shock 1984;14:223–35.PubMedGoogle Scholar
  21. [21]
    Denzlinger C, Guhlmann A, Scheuber PH, Wilker D, Hameer D, Keppler D. Metabolism ana analysis of cysteinyl leukotrienes in the monkey. J Biol Chem 1986;261:15601–6.PubMedGoogle Scholar
  22. [22]
    Reitman S, Frankel S. A colorimetric determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. Am J Pathol 1957;28:56–63.Google Scholar
  23. [23]
    White WL, Erickson MM, Stevens SC, editors. Chemistry for the Clinical Laboratory. St. Louis: CV Mosby, 1976:228–32.Google Scholar
  24. [24]
    Meister A, Tate SS, Griffith OW, ψ-Glutamyltranspeptidase. Meth Enzymol 1981;77:237–53.CrossRefGoogle Scholar
  25. [25]
    Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.Google Scholar
  26. [26]
    Denzlinger C, Rapp S, Hagmann W, Keppler D. Leukotrienes as mediators in tissue trauma. Science 1985;230:330–2.CrossRefGoogle Scholar
  27. [27]
    Wettstein M, Gerok W, Haussinger D. Metabolism of cysteinyl leukotrienes in non-recirculating rat liver perfusion. Eur J Biochem 1989;181:115–24.CrossRefGoogle Scholar
  28. [28]
    Watkins JB III, Sherman SE. Long-term diabetes alters the hepatobiliary clearance of acetaminophen, bilirubin and digoxin. J Pharmacol Exp Ther 1992;260:1337–43.PubMedGoogle Scholar
  29. [29]
    Utili R, Abernathy CO, Zimmerman HJ. Cholestatic effects of Escherichia coli endotoxin on the isolated perfused rat liver. Gastroenterol 1976;70:248–53.Google Scholar
  30. [30]
    Tritapepe R, Dipadova C, Rovagnati P. Spontaneous reversal of ethinyl estradiol-induced cholestasis in the rat. Experientia 1980;36:580–1.CrossRefGoogle Scholar
  31. [31]
    Roelofsen H, Schoemaker B, Bakker C, Ottenhoff R, Jansen PLM, Oude Elferink RPJ. Impaired hepatocanalicular organic anion transport in endotoxemic rats. Am J Physiol 1995;269:G427–34.PubMedGoogle Scholar
  32. [32]
    Hagmann W, Denzlinger C, Keppler D. Production of peptide leukotrienes in endotoxin shock. FEBS Lett 1985;180:309–13CrossRefGoogle Scholar
  33. [33]
    Meng XJ, Wang JL. Arachidonic acid metabolism in galactosamine/endotoxin. J Tonji Med Univ 1994;14:169–72.CrossRefGoogle Scholar
  34. [34]
    Hammarstrom S. Metabolism of leukotriene C3 in the guinea pig. Identification of metabolites formed by lungs, liver and kidney. J Biol Chem 1981;256:9573–8.PubMedGoogle Scholar
  35. [35]
    Penrose JF, Gagnom L, Goppelt-Struebe M, Myers P, Lam BK, Jack RM, et al. Purification of human leukotriene C4 synthase. Proc Natl Acad Sci USA 1992;89:11603–6.CrossRefGoogle Scholar
  36. [36]
    Hagmann W, Denzlinger C, Rapp S, Weckbecker G, Keppler D. Identification of the major endogenous leukotriene metabolite in the bile of rats as N-acetyl leukotriene E4. Prostaglandins 1986;31:239–51.CrossRefGoogle Scholar
  37. [37]
    Wendel A, Tiegs G. Leukotriene D4 mediates galactosamine/ endotoxin-induced hepatitis in mice. Biochem Pharmacol 1987;36:1867.CrossRefGoogle Scholar
  38. [38]
    Pfeifer CA, Bottoms GD, Johnson MA, Fessler J. Leukotriene C4 disposition and metabolism in the anesthetized and endotoxemic dog. Circ Shock 1991;33:68–83.PubMedGoogle Scholar
  39. [39]
    Huber M, Guhlmann A, Jansen PLM, Keppler D. Hereditary defect of hepatobiliary cysteinyl leukotriene elimination. Hepatology 1987;7:224–8.CrossRefGoogle Scholar
  40. [40]
    Denzlinger C, Guhlman A, Hagmann W, Scheuber PH, Scheyerl F, Wilker D, et al. Cysteinyl leukotrienes undergo enterohepatic circulation. Prostagland Leukotr Med 1986;21: 321–2.CrossRefGoogle Scholar
  41. [41]
    Enderle GJ, Delebar U, Krell H. Different pathomechanisms of altered biliary leukotriene C4 elimination in isolated perfused rat livers. Biochem Pharmacol 1995;94:297–304.CrossRefGoogle Scholar
  42. [42]
    Simon FR, Arias I. Alteration of bile canalicular enzymes in cholestasis. A possible cause of bile secretory failure. J Clin Invest 1973;52:765–75.CrossRefGoogle Scholar
  43. [43]
    Smith DJ, Gordon ER. Role of liver plasma membrane fluidity in the pathogenesis of estrogen-induced cholestasis. J Lab Clin Med 1988;112:679–85.PubMedGoogle Scholar
  44. [44]
    Adlercreutz H, Tenhunen R. Some aspects of the interaction between natural and synthetic female sex hormones and the liver. Am J Med 1970;49:630–48.CrossRefGoogle Scholar
  45. [45]
    Jaeschke H, Trummer E, Krell H. Increase in biliary permeability subsequent to intrahepatic cholestasis by estradiol valerate in rats. Gastroenterology 1987;93:533–8.CrossRefGoogle Scholar
  46. [46]
    Kreek MJ. Female sex steroids and cholestasis. Sem Liver Dis 1987;7:8–23.CrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag 1996

Authors and Affiliations

  • H. M. Omar
    • 1
  • R. A. Sanders
    • 1
  • J. B. WatkinsIII
    • 1
  1. 1.Medical Sciences ProgramIndiana University School of MedicineBloomingtonUSA

Personalised recommendations